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Abstract: Obesity is a well-known risk factor for renal cell carcinoma (RCC) development. However,
the RCC–obesity link has not been fully addressed when considering a comprehensive scenario
starting from pathogenetic aspects through pathological issues up to the outcome of medical treatment.
We therefore conducted an electronic PubMed search using keywords “obesity”, “body mass index”,
“overweight”, “renal cell carcinoma/kidney cancer”, “medical treatment”, “targeted therapy”, and
“immunotherapy/immune checkpoint inhibitors”. The selected data supported a crosstalk between
adipose tissue (adipocytes and other white adipose tissue cells) and cancer cells inducing several
signaling pathways that finally stimulated angiogenesis, survival, and cellular proliferation. Accurate
sampling of renal sinus fat correlated with a prognostic value. Retrospective clinical evidence in
metastatic RCC patients with higher body mass index (BMI) and treated with targeted therapies
and/or immune checkpoint inhibitors showed advantageous survival outcomes. Therefore, obesity
may influence the course of RCC patients, although the interplay between obesity/BMI and RCC
warrants a large prospective confirmation. We are therefore still far from determining a clear role
of obesity as a prognostic/predictive factor in metastatic RCC patients undergoing targeted therapy
and immunotherapy.
Keywords: obesity; body mass index; renal cell carcinoma; targeted therapy; immunotherapy;
clinical outcomes
1. Introduction
Renal cell carcinoma (RCC) is considered the most lethal cancer among the common genitourinary
malignances [1]. RCC accounts for approximately 4% of all new cancers worldwide [2], and shows
an increasing rate of incidence in the US, while the rate in Western Europe has been stable in the last
decade. The majority of patients are males aged between 60 and 70 years.
Surgery, conservative where possible, is the current best practice for the treatment of localized or
locally advanced RCC. It should be borne in mind that approximately 30% of patients who undergo
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partial or radical nephrectomy will develop distant metastases during their lifetime [2]. Furthermore,
about 20% to 25% of RCC patients present metastatic disease at first diagnosis. Choosing the best
therapeutic approach is fundamental in order to avoid unnecessary toxicities and optimize the
outcome of RCC patients. In recent years, several agents have been developed that have substantially
improved the prognosis of RCC patients. These agents target the vascular endothelial growth factor
(VEGF; bevacizumab) and its receptor (VEGFR; sunitinib, sorafenib, pazopanib, axitinib, cabozantinib,
lenvatinib, and tivozanib), mammalian target of rapamycin (mTOR; temsirolimus and everolimus),
immunocheckpoints programmed death-1 (PD-1; nivolumab and pembrolizumab) and its ligand
(PD-L1; atezolizumab), and cytotoxic T lymphocyte antigen 4 (CTLA-4; ipilimumab). Although major
advances have been made in understanding the molecular basis of RCC carcinogenesis and metastatic
spread, the choice of therapeutic sequence for each patient is still mainly based on clinical considerations.
Together with smoking habits and hereditary syndromes related to mutations in the von
Hippel-Lindau (VHL) gene, obesity is a risk factor for RCC. Obesity is a worldwide debilitating
disease, defined as a body mass index (BMI) exceeding 30 kg/m2, and characterized by a growth of
white adipose tissue (WAT) [3]. Epidemiologically, it is well known that there is a close association of
obesity with several non-cancer medical conditions such as glucose intolerance up to type 2 diabetes,
dyslipidemia, metabolic syndrome, and cardiovascular diseases. In the field of cancer prevention,
obesity is the second most common cause of carcinogenesis, after smoking [4]. Bearing in mind that
the expansion of visceral WAT, which causes abdominal obesity, has been closely related to cancer
cell growth [5], and assuming that by 2025 the worldwide obesity incidence is estimated to reach 21%
in women, it is indisputable that the relationship between cancer and obesity is an extremely crucial
health topic.
During recent decades, a large amount of data has been extensively analysed to investigate the
impact of obesity/BMI on RCC occurrence, and as a result, a strong correlation in terms of carcinogenesis
has been recognized, leading to obesity becoming one of the established and modifiable risk factors
of RCC development both in men and women [6,7]. However, the relationship between obesity and
RCC is still not completely understood for all stages of disease; in fact, studies on the relationship
between obesity and RCC survival have yielded conflicting results [8,9]. Recent data underline that
40% of all cancer deaths in the United States are mainly caused by obesity [10], and an increased rate of
obesity-induced mortality has been proved for many cancers, including RCC.
Recently, our group published a review article focusing on the role of obesity in genitourinary
cancers with a particular focus on urothelial and prostate cancers. The available evidence underlined
intriguing although often controversial results on the association of obesity/BMI with clinical outcomes
of tumor response to therapies and survival outcomes [11].
Based on this scenario and taking into account the serious clinical-pathological implications
arising, the current work examines the influence of obesity in metastatic RCC patients, focusing firstly
on pathogenetic aspects concerning several signaling pathways, and then addressing pathological
issues before examining the outcomes of targeted therapy and immunotherapy.
2. Article Selection
We conducted an electronic search of the PubMed database of the US National Library
of Medicine, using keywords “obesity” or “body mass index” or “overweight” combined with
“renal cell carcinoma/kidney cancer” along with “medical treatment” or “targeted therapy” or
“immunotherapy/immune checkpoint inhibitors”. Gaetano Aurilio, Francesco Piva, and Matteo
Santoni reviewed the most relevant articles published in English in conjunction with their references,
and a selection was made for the present article. For article selection, priority was given to scientific
articles published within the last 5 years.
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3. Cancer–Obesity Link
White adipose tissue (WAT) is a complex cellular system harboring many other cells in addition
to adipocytes, such as adipose stromal cells (ASCs), which fuel the endothelium and generate
adipocyte progenitors [11], and a broad spectrum of innate and adaptive immune cells such as T
and B lymphocytes, macrophages, dendritic cells, neutrophils, and mast cells. These cell types
cooperate to produce proactive substances involved in the regulation of signaling pathways leading to
carcinogenesis promotion.
Indeed, the biological cancer–obesity link is still yet to be fully defined, although a plethora of
molecular mechanisms have been extensively investigated and postulated regarding the influence of
obesity-driven biomarkers on cancer risk and progression. Possible biological mechanisms such
as adipokines (leptin, adiponectin), insulin/insulin-like growth factor (IGF) pathways, chronic
inflammation, and sex steroids have been implicated, along with various postulated molecules
such as ceruloplasmin, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), gastric inhibitory
polypeptide (GIP), C-peptide, peptide YY, pancreatic polypeptide, and plasminogen activator
inhibitor-1. These adipocyte-linked molecules come into direct contact with cancer cells via blood
circulation, where they induce several cellular pathways, finally stimulating angiogenesis, survival, and
proliferation of cancer cells [11]. Here we describe some of these pathways, as follows (Figure 1) [11].
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Figure 1. Pathways show the influence of adipocytes on cancer. The substances released from 
adipocytes diffuse through the blood circulation and reach cancer cells, where they activate different 
cellular pathways leading to an increase of cell proliferation, survival, and angiogenesis. IGF1: 
insulin-like growth factor I. IGF1R: insulin-like growth factor 1 receptor. INSR: insulin receptor. IRS1: 
insulin receptor substrate 1. BAD: Bcl2-associated agonist of cell death. MAPK: mitogen-activated 
protein kinase. LEPR: leptin receptor. ADIPOR1: adiponectin receptor protein 1. ADIPOR2: 
adiponectin receptor protein 2. VEGFA: vascular endothelial growth factor A. AMPK: AMP-activated 
protein kinase. mTOR: serine/threonine-protein kinase mTOR. CP: ceruloplasmin. SLC31A1: high-
affinity copper uptake protein 1. TNF: tumor necrosis factor. TNFRSF: tumor necrosis factor receptor 
superfamily. IL6: interleukin-6. IL6R: interleukin-6 receptor subunit alpha. PTGS2: prostaglandin G/H 
synthase 2. PI3K: phosphoinositide 3-kinases. AKT: serine/threonine kinase. HIF1A: hypoxia-
inducible factor 1-alpha. 
4. Pathological Assessment and Prognostic Value of Adipose Tissue in RCC 
According to the AJCC/TNM 8th Edition, invasion of perirenal and/or renal sinus adipose tissue 
by a kidney tumor should be considered as pT3a stage, independently of tumor histotype or tumor 
dimension [22–24]. The extension beyond Gerota’s fascia, including contiguous extension into the 
ipsilateral adrenal gland, should be considered as pT4 stage [22–24]. As a consequence of this staging 
system and of the prognostic value of perinephric fat invasion, accurate sampling of the perirenal 
and renal sinus fat is of great importance. Special attention should be paid to the assessment of 
perinephric fat invasion. Macroscopically, a pushing border with smooth convex outer surface, even 
if beyond the normal kidney, is not diagnostic of fat invasion. Loss of smooth interface or irregular 
nodules protruding into fat are likely to be diagnostic of invasion of perinephric fat. In such case, 
multiple perpendicular sections of the tumor fat interface are necessary. At microscopic examination, 
tumor cells touching adipose tissue or tumor nests extending as irregular tongues into fat, with or 
without desmoplasia, are diagnostic aspects of invasion [23–25]. 
The renal sinus is the adipose tissue compartment located within the confines of the kidney not 
delimited from the renal cortex by a fibrous capsule surrounding numerous veins and lymphatic 
Figure 1. Pathways show the influence of adipocytes on cancer. The substances released from adipocytes
diffuse through the blood circulation and reach cancer cells, where they activate different cellular
pathways leading to an increase of cell proliferation, survival, and angiogenesis. IGF1: insulin-like
growth factor I. IGF1R: insulin-like growth factor 1 receptor. INSR: insulin receptor. IRS1: insulin
receptor substrate 1. BAD: Bcl2-associated agonist of cell death. MAPK: mitogen-activated protein
kinase. LEPR: leptin receptor. ADIPOR1: adiponectin receptor protein 1. ADIPOR2: adiponectin
receptor protein 2. VEGFA: vascular endothelial growth factor A. AMPK: AMP-activated protein kinase.
mTOR: serine/threonine-protein kinase mTOR. CP: ceruloplasmin. SLC31A1: high-affinity copper
uptake protein 1. TNF: tumor necrosis factor. TNFRSF: tumor necrosis factor receptor superfamily. IL6:
interleukin-6. IL6R: interleukin-6 receptor subunit alpha. PTGS2: prostaglandin G/H synthase 2. PI3K:
phosphoinositide 3-kinases. AKT: serine/threonine kinase. HIF1A: hypoxia-inducible factor 1-alpha.
A condition known as insulin-resistance does exist in obese patients and is associated with high
levels of insulin-like growth factor I (IGF1) and blood insulin. Insulin-like growth factor 1 receptors
(IGF1R) and insulin receptors (INSR) are generally up-regulated and, in turn, through the interaction
with insulin recep or substrate 1 (IRS1) prime PI3K/AKT, mTOR/cyclin D1, mTOR/HIF1A/VEGF,
and Ras pathways, finally induce cellular proliferation/angiogenesis and block apoptosis [12,13].
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Moreover, obese patients have a high level of the hormone leptin, which interacts with its
receptor (LEPR) stimulating cancer proliferation and survival by also involving MAPK, Jak/Stat,
and PI3K/AKT pathways. Adiponectin in turn, through its receptors ADIPOR1 and ADIPOR2, has an
anti-mTOR effect, thereby inhibiting the angiogenesis process [14]. Furthermore, obese patients exhibit
high levels of ceruloplasim, an adipose tissue-induced substance, which interacts with its SLC31A1
receptor producing VEGF and consequently stimulating cancer angiogenesis [15]. Pro-inflammatory
cytokines, in particular TNF-α and IL-6, trigger the production of cyclooxygenase 2 (COX2 or PTGS2),
which in turn produces prostaglandin E2 (PGE2), favoring cancer progression. Of note, PGE2 may
cause the release of inflammatory and angiogenic factors by cancer cells and hence contribute to
changing the cancer microenvironment into an immunosuppressive environment. The activation
of transcription factor NF-kb TNF-α increases anti-apoptotic factors such as BCL-2 and survivin.
These, in turn, enhance cancer cell survival through an increase of cyclin D1 and cyclin E, which
stimulate cellular proliferation, and the increase of several cytokines, e.g. IL-1, IL-2, and IL-6, with
pro-inflammatory action. The complex IL-6/IL-6 receptor induces the PI3K/AKT pathway, which
results in the enhancement of cancer cell proliferation and an anti-apoptotic effect.
Such crosstalk between adipose tissue (adipocytes and other WAT cells) and cancer can be
summarized by the following sequence of steps: (i) in obese patients, cancer induction can be
elicited via chronic inflammation in fat tissue and inflammation evoked by cytokines and chemokines
as well as extracellular matrix enzymes, which in turn damages the genetic information within
the cells causing mutations resulting in carcinogenesis; (ii) fat-tissue-derived cells that infiltrate
cancer cells release adipokine signaling that can power cancer development; (iii) both adipocytes
producing fatty acids/metabolites and the immune system dysregulation together can promote cancer
aggressiveness [16]. Cellular interactions are regulated via adipocyte-induced paracrine and contact
signals, while the stimulation of the innate and adaptive immune system comes about through
adipocyte death generated by compromised oxygen supply [17]. To substantiate how a biological
mechanism supports obesity-related cancer development, we propose the adipose fatty acid binding
protein (A-FABP), which is another critical mediator predominantly expressed in mature adipocytes
and involved in lipid transport, intracellular modulation of lipid metabolism, and gene expression
regulation. Elevated human serum levels of A-FABP were observed in obesity [18], and correlated with
breast cancer growth [19]. Of interest, Hao and co-workers used human samples and mouse models
to show that (i) increased circulating A-FABP levels were found in obese patients with breast cancer;
(ii) circulating A-FABP induced breast cancer aggressiveness in both in vitro and in mouse models;
(iii) A-FABP promoted breast cancer stemness through the IL6/STAT3/ALDH1 signaling pathway;
(iv) A-FABP ablation decreased obesity-associated breast cancer growth in different mouse models [20].
This study provided novel evidence for the linkage between obesity and breast cancer development,
as further emphasized by Greenhill on Nature Reviews Endocrinology in October 2018 [21], and
underlined the activity of common signaling pathways across different cancers.
4. Pathological Assessment and Prognostic Value of Adipose Tissue in RCC
According to the AJCC/TNM 8th Edition, invasion of perirenal and/or renal sinus adipose tissue
by a kidney tumor should be considered as pT3a stage, independently of tumor histotype or tumor
dimension [22–24]. The extension beyond Gerota’s fascia, including contiguous extension into the
ipsilateral adrenal gland, should be considered as pT4 stage [22–24]. As a consequence of this staging
system and of the prognostic value of perinephric fat invasion, accurate sampling of the perirenal and
renal sinus fat is of great importance. Special attention should be paid to the assessment of perinephric
fat invasion. Macroscopically, a pushing border with smooth convex outer surface, even if beyond
the normal kidney, is not diagnostic of fat invasion. Loss of smooth interface or irregular nodules
protruding into fat are likely to be diagnostic of invasion of perinephric fat. In such case, multiple
perpendicular sections of the tumor fat interface are necessary. At microscopic examination, tumor
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cells touching adipose tissue or tumor nests extending as irregular tongues into fat, with or without
desmoplasia, are diagnostic aspects of invasion [23–25].
The renal sinus is the adipose tissue compartment located within the confines of the kidney not
delimited from the renal cortex by a fibrous capsule surrounding numerous veins and lymphatic
vessels. The proliferation of adipose tissue in this compartment configures a lesion called renal sinus
lipomatosis, characterized by benign proliferation of fat and atrophy of the renal parenchyma (Figure 2).
It is often associated with chronic pyelonephritis, renal lithiasis, and hydronephrosis, and occurs with
advanced age, obesity, and exposure to steroids [26,27].
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Involvement of renal sinus fat appears to indicate a worse prognosis than involvement of only
perirenal adipose tissue. Thompson et al. analyzed 205 pT3a clear cell RCC patients and found
that patients with renal sinus fat invasion were 63% more likely to die of RCC compared with those
with perinephric fat invasion, and that the risk of death persisted in multivariate analysis after
adjusting for regional lymph nodes and distant metastases [29]. These results were confirmed by
Bertini et al., who found a 5-year cancer specific survival (CSS) of 71.9% for pT3a/N0/M0 RCC patients
with perinephric fat invasion only compared to 45.5% CSS for patients with sinus fat invasion [34].
As the relevance of this parameter has been described only recently, retrospective studies conducted
on material without adequate sampling of the renal sinus should be considered with caution [35,36].
5. Obesity and RCC Risk
Epidemiological evidence collected during the 1990s highlighted a closer connection of obesity
with RCC in females [37]. However, more recently, this relationship has been documented equally in
both sexes [38]. A large prospective study was conducted over 8 years in patients in the United States
assessing the relationship of RCC occurrence with weight measurements at predefined time-points.
The results showed an association between baseline BMI and RCC risk, with further risk when
documenting an increased BMI at age 50. Interestingly, weight gain equal to or exceeding 20 kg from
younger age to 35 years or from age 35 to 50 was significantly correlated with RCC risk [39].
In 2013, Dobbins and co-workers published the results of a meta-analysis based on 98 observational
RCC studies from 1985 and 2011 in which the association between obesity and cancer risk was
assessed [40]. In comparison with people with normal BMI, the authors determined the relative risk of
RCC as 1.57 in obese men and 1.72 in obese women, respectively [40]. Of interest, in a large Swedish
male population, the relative risk of RCC occurrence was 1.8 and increased in persons presenting a
BMI progressively higher by 15% over a range of 6 years compared with those without body weight
variations [41].
The importance of BMI as risk factor has also been demonstrated by the attempt to incorporate
it into novel stratification criteria for RCC patients treated with immune checkpoint inhibitors.
Martini et al. [42] retrospectively reviewed a patient population mainly treated with anti-PD-1 as
monotherapy, in which three variables, namely BMI, monocyte-to-lymphocyte ratio (MLR), and
metastatic sites, were selected for identifying poor-risk patients (BMI < 24, metastases > 2 with liver
metastases, and MLR > 0.93) and good-risk patients (BMI > 24, MLR < 0.93, and metastases < 2).
The results demonstrated that in poor-risk patients, both overall survival (OS) and progression-free
survival (PFS) were significantly shorter than in good-risk patients, suggesting that the variables used
are promising factors for predicting survival [42].
Emerging data indicate a causal relationship between methylation of obesity-genes and RCC
occurrence. Interesting data from a panel of 20 obesity-correlated genes from kidney biopsy samples
demonstrated that patients with high levels of leptin receptor methylation were at risk of increased
recurrence with consequent significantly shorter recurrence-free survival with respect to patients with
low levels of leptin receptor methylation [43]. Most recently, Wang et al. [44] published a retrospective
case-control study in which the association between circulating levels of a panel of 14 obesity-related
biomarkers and clear-cell RCC risk was assessed. The findings highlighted that individuals with high
levels of C-peptide, IL-6, and TNF-α had a significantly higher clear-cell RCC risk compared with
those with low levels of these biomarkers [44]. The implications of this evidence further support the
role of chronic inflammation and the insulin pathway in the pathogenic growth of RCC.
Furthermore, some evidence indicated that fatty acid synthase (FASN) expression was correlated
with worse outcomes in RCC [45,46]. In this regard, data from The Cancer Genome Atlas dataset
showed that FASN gene expression was inversely correlated with BMI (p = 0.034), and median OS
was longer in patients with low FASN expression (36.8 v 15.0 months; p = 0.002). Of note, FASN
immunohistochemistry positivity was significantly higher (p = 0.015) in poor-risk patients (48%)
compared with intermediate (34%) and good-risk (17%) patients [47].
Int. J. Mol. Sci. 2019, 20, 5683 7 of 13
The association between metabolic factors and the risk of RCC has also been investigated. In a
large prospective study within the Metabolic Syndrome and Cancer Project (Me-Can), clinical data on
blood pressure, BMI, blood glucose, cholesterol, and triglycerides were collected from a population
of 560,388 subjects. Taken separately, high glucose and triglycerides levels, as well as high BMI and
blood pressure were correlated with an increased risk of RCC among men, while only BMI had a
significant correlation among women. Interestingly, blood pressure and triglycerides among men
and BMI among women were independently associated with an increased risk of RCC; however,
no biological interaction was discovered between the factors assessed and RCC risk [48]. These data
underline the importance of certain metabolic factors, although is indisputable that further studies are
needed to shed light on the interplay between metabolic profiles and the risk of RCC development.
6. Obesity and Response of RCC to Medical Therapies
Currently, while the therapeutic options for metastatic RCC patients have been expanded with
the introduction of immunotherapies and new TKIs, on the other hand, the lack of validated predictive
factors to accurately guide oncologists’ decisions is still an unsolved challenging issue.
Several studies have examined the prognostic/predictive role of obesity in metastatic RCC patients
undergoing systemic therapy (Table 1). In a heterogeneous group of 116 metastatic RCC patients treated
with antiangiogenic agents (mainly sunitinib) as first-line treatment, Steffens et al. retrospectively
observed that visceral fat area (VFA) and subcutaneous fat area (SFA) were predictive biomarkers of
longer PFS and OS, while BMI and body surface area (BSA) were not [49]. In contrast, in metastatic RCC
patients receiving targeted agents (n = 64) or immunotherapy (n = 49), VFA and SFA were significantly
correlated with shorter PFS and OS [50]. More recently, Mizuno and colleagues [51] used BMI and VFA
as obesity indices to evaluate the correlation with survival outcomes in 114 patients with metastatic RCC
and receiving systemic therapy; most study patients were treated with VEGFR-TKIs, mainly sunitinib
and sorafenib, and a few patients received temsirolimus and cytokine. The authors demonstrated that
VFA was significantly associated with improved PFS (p = 0.007) and OS (p = 0.0001); in addition, VFA
resulted to be an independent predictive factor of survival [51]. The implications of BMI on OS and
on treatment outcomes were investigated in two large metastatic RCC patient populations receiving
anti-VEGF receptor and mTOR inhibitors. Both in the International Metastatic Renal Cell Carcinoma
Database Consortium (IMDC) cohort including 1975 patients and in the external validation cohort of
4657 patients, high BMI was correlated with a more favorable OS compared to patients with low BMI.
This result was maintained when matching with IMDC prognostic criteria. The authors concluded
that a high BMI may be a prognostic factor of better survival outcomes in metastatic RCC patients
who received targeted therapy, both in first- and second-line settings [47]. This is similar to the results
published by Choueiri and his colleagues [52], who reported a survival advantage for obese patients
with metastatic RCC treated with targeted therapies. In this study, 475 patients who received sunitinib
(61%), sorafenib (30%), or bevacizumab (9%) were stratified according to BMI. Median OS was 1 year
longer in obese RCC patients (p = 0.0001), and obesity was an independent factor for better OS in the
multivariate analysis adjusting for the Heng prognostic risk groups (HR = 0.67, p = 0.01) [52].
Of interest, in 71 metastatic RCC patients under first-line sunitinib treatment, Ishihara and
co-workers [53] retrospectively evaluated the impact of cancer cachexia on survival through two
indicators, namely sarcopenia and the modified Glasgow prognostic score (mGPS). Selected parameters
for muscle tissue computed tomography-scan derived and matched with BMI allowed to define the
condition of sarcopenia; the mGPS was instead assessed through the level of C-reactive protein (CRP)
and albumin (high mGPS was equal to CRP > 1.0 mg/dL and albumin < 3.5 g/dL). The results showed
that sarcopenia was markedly correlated with shorter median PFS and median OS, in contrast to
non-sarcopenic patients, and that patients with higher mGPS significantly displayed inferior PFS and
OS. In the multivariate analysis, sarcopenia and mGPS were independent predictors of reduced PFS
and OS, respectively [53].
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Table 1. Obesity biomarkers and RCC response to medical therapies.
First Author (Year) TrialDesign SS Drugs Class Obesity Biomarkers Outcome
Albiges (2016) [47] R 6632 TKIs BMI BMI ↑ = improved OS
Steffens (2011) [49] R 116 TKIs VFA and SFA improved PFS/OS
Ladoire (2011) [50] R 113 TKIs or ICI VFA and SFA shorter PFS/OS
Mizuno (2017) [51] R 114 TKIs BMI and VFA VFA: improved PFS/OS
Choueiri (2019) [52] R 475 TKIs BMI Obese patients = improved OS
Ishihara (2016) [53] R 71 TKIs Sarcopenia and mGPS shorter PFS/OS
Martini (2019) [54] R 65 TKIs BMI BMI ↑ = improved OS
Lalani (2019) [55] R 147 TKIs + ICI BMI BMI ↑ = improved OS
De Giorgi (2019) [56] R 313 ICI BMI normal BMI = shorter OS
Motzer (2019) [57] R 886 ICI + TKIs BMI no interference on survival
Abbreviations: SS, sample size; R, retrospective; TKIs, tyrosine kinase inhibitors; VFA, visceral fat area; SFA, s.c. fat
area; ICI, immune checkpoint inhibitors; BMI, body mass index; mGPS, modified Glasgow prognostic score; PFS,
progression-free survival; OS, overall survival; ↑, high.
In February 2019, at the American Society of Clinical Oncology Genitourinary Symposium,
Martini et al. [54] presented their retrospective results of 65 RCC patients treated with cabozantinib.
The majority of patients had a BMI > 25, and almost all were classed as intermediate/poor-risk.
The results showed that higher BMI was significantly correlated with longer OS, without showing
significant differences in terms of gastrointestinal and other drug-related toxicities [54].
The relationship between obesity and the outcome of patients treated with immune checkpoint
inhibitors has also been investigated. In this regard, Lalani et al. [55] retrospectively collected data
from 147 patients treated with immunotherapy alone or in combination with targeted therapies. At a
median follow-up of 25 months, patients with high BMI (>25) had longer median OS compared with
low BMI (<25) patients (34 vs. 16 months, 2-year OS 61 vs. 42%, p = 0.016), while only a non-significant
trend was registered for PFS (8.2 vs. 5.9 months, p = 0.400). Interestingly, patients who presented a
BMI reduction during immunotherapy from >25 to <25 had shorter OS (HR = 2.25, 0.94–5.35) than did
those with no BMI changes.
In this regard, a cooperative Italian group headed by De Giorgi carried out a post hoc analysis
of a large population of metastatic RCC patients treated with nivolumab immunotherapy within an
Italian Expanded Access Program to investigate the prognostic relevance of BMI along with measures
of inflammation (neutrophil-to-lymphocyte ratio, systemic immune index (SII), platelet-to-lymphocyte
ratio). In univariate and multivariate analyses, BMI was found to be significantly associated with OS;
in particular, patients with normal BMI (<25 kg/m2) along with SII > 1.375 had shorter OS than did
patients with no risk factors. The authors concluded that BMI was an independent prognostic factor in
nivolumab RCC patients [56].
The relevance of BMI as a risk factor does not routinely place it as a predictor of prognosis in
clinical settings. Only recently, in a phase III trial comparing avelumab plus axitinib versus sunitinib in
previously untreated metastatic RCC patients, BMI appeared in a subgroup analysis. However, this
was not a preplanned statistical analysis but a post hoc exploratory analysis. The combination with
avelumab plus axitinib performed better than sunitinib regardless of BMI status (<25 or >25) [57].
7. Concluding Remarks
The selected clinical data from metastatic RCC patients with obesity or increased BMI that we
present in this work seem to generally indicate a promising survival benefit, both under targeted
therapies and using immunotherapies.
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Currently, treatment decision-making in metastatic RCC patients does not take into account
whether a patient is habitually obese or non-obese. Indeed, obesity as well as other clinical features
including age, gender, and ethnicity have not been prospectively validated as a predictive biomarker
of response to therapy. Together with the lack of molecular predictive factors and, as is well known,
the controversial role of PD-L1 expression in patients treated with immune checkpoint inhibitors,
there emerges a dramatic need for prospective trials aimed at definitively assessing the influence of
these factors on the outcomes of RCC patients. Whether BMI or VFA/SFA are the best factors for
treatment monitoring in RCC patients is still an open and intriguing question.
Some researchers have defined the relationship between obesity and RCC as an “apparent obesity
paradox” [47]. In such sense, it has been proposed that the correlation between high BMI and longer OS
can be explained considering the heterogeneity of RCC and, in particular, less aggressive histological
subtypes [58]. This view has been further reinforced by the demonstration in obese patients of
downregulated FASN expression [47].
In recent years, microbiota as emerged has a promising therapeutic target in patients with lung
and RCC who receive immunotherapeutic approaches. This is mainly based on the results published
by Routy et al. [59], reporting that primary resistance to immune checkpoint inhibitors may be
associated with abnormal gut microbiome composition, as demonstrated by the enhanced response to
immunotherapy obtained via the transplantation of fecal microbiota from responders into germ-free or
antibiotic-treated mice. In this setting, the close relationship between the composition and function of
gut microbiota and obesity seems to merit careful consideration. Notwithstanding, the link between
microbiota and obesity or obesity-related conditions (including type 2 diabetes) has not yet been
completely clarified. Among the proposed mechanisms, altered integrity of the gut barrier and of the
capacity to extract energy from foods, together with changes in the modulation of chronic inflammation,
seem to be the most probable candidates [60].
Promising results in in vivo models have recently been observed with novel therapeutics targeting
adipocytes, ASCs, and adipose endothelium [61,62], paving the way for tailored therapies for obese
patients. In the near future, the challenge will be that of targeting cellular pathways of WAT growth
prone to cancer induction and progression in an attempt to reduce cancer risk [63]. Novel evidence
has recently reinforced the role of insulin as risk factor; however, it appears clear that there is an
unequivocal need to understand how the insulin pathway increases the risk of RCC and to discover
further biological pathways as well as obesity-related mechanisms involved in RCC growth. Of interest,
cellular pathways involved in the switch of cancer cells to lipid metabolism could be potential
targets along with conventional therapies. Areas of investigation for explaining how obesity affects
clinical outcomes should consider both pharmocokinetics and drug bioavailability, in addition to the
concomitance of cardiovascular disease and diabetes. It is conventionally known that obesity elicits a
biological condition of inflammation with consequent increases in TNF, interleukins, C-reactive protein,
etc. However, it is important to note that not all obese patients express inflammation of the adipose
tissue or metabolic complications.
To conclude, since the incidence of obesity is rising, and its implications can have serious medical
consequences, the interplay between obesity and cancer warrants further investigation by the scientific
community worldwide. Although several studies are focused on the treatment and prevention of
RCC, the first stones on the path toward targeted therapy development for RCC patients are only just
beginning to be laid.
Author Contributions: Conceived and designed: G.A., F.P., M.S., R.M. Wrote the paper: G.A., F.P., M.S., R.M.,
A.C. Read and revised the manuscript, accepted the final version: G.A., F.P., M.S., A.C., G.S., A.L.-B., L.C., N.B.,
F.N., R.M.
Funding: This research received no external funding.
Acknowledgments: The authors thank William Russell-Edu for revising the English manuscript.
Conflicts of Interest: The authors declare no conflict of interest.
Int. J. Mol. Sci. 2019, 20, 5683 10 of 13
References
1. Arabsalmani, M.; Mohammadian-Hafshejani, A.; Ghoncheh, M.; Hadadian, F.; Towhidi, F.; Vafaee, K.;
Salehiniya, H. Incidence and mortality of kidney cancers, and human development index in Asia; a matter of
concern. J. Nephropathol. 2017, 6, 30–42. [CrossRef] [PubMed]
2. Kabaria, R.; Klaassen, Z.; Terris, M.K. Renal cell carcinoma: Links and risks. Int. J. Nephrol. Renovasc. Dis.
2016, 9, 45–52. [PubMed]
3. Lee, S.J.; Shin, S.W. Mechanisms, Pathophysiology, and Management of Obesity. N. Engl. J. Med. 2017,
376, 1491–1492. [PubMed]
4. Budny, A.; Grochowski, C.; Kozłowski, P.; Kolak, A.; Kamin´ska, M.; Budny, B.; Abramiuk, M.; Burdan, F.
Obesity as a tumour development triggering factor. Ann. Agric. Environ. Med. 2019, 26, 13–23. [CrossRef]
5. Allott, E.H.; Masko, E.M.; Freedland, S.J. Obesity and prostate cancer: Weighing the evidence. Eur. Urol.
2013, 63, 800–809. [CrossRef]
6. Chow, W.H.; Gridley, G.; Fraumeni, J.F., Jr.; Järvholm, B. Obesity, hypertension, and the risk of kidney cancer
in men. N. Engl. J. Med. 2000, 343, 1305–1311. [CrossRef]
7. Johansson, M.; Carreras-Torres, R.; Scelo, G.; Purdue, M.P.; Mariosa, D.; Muller, D.C.; Timpson, N.J.;
Haycock, P.C.; Brown, K.M.; Wang, Z.; et al. The influence of obesity-related factors in the etiology of renal
cell carcinoma-A mendelian randomization study. PLoS Med. 2019, 16, e1002724. [CrossRef]
8. Hakimi, A.A.; Furberg, H.; Zabor, E.C.; Jacobsen, A.; Schultz, N.; Ciriello, G.; Mikklineni, N.; Fiegoli, B.;
Kim, P.H.; Voss, M.H.; et al. An epidemiologic and genomic investigation into the obesity paradox in renal
cell carcinoma. J. Natl. Cancer Inst. 2013, 105, 1862–1870. [CrossRef]
9. Steffens, S.; Ringe, K.I.; Schroeer, K.; Lehmann, R.; Rustemeier, J.; Wegener, G.; Schrader, M.; Hofmann, R.;
Kuczyk, M.A.; Schrader, A.J.; et al. Does overweight influence the prognosis of renal cell carcinoma? Results
of a multicenter study. Int. J. Urol. 2013, 20, 585–592. [CrossRef]
10. Steele, C.B.; Thomas, C.C.; Henley, S.J.; Massetti, G.M.; Galuska, D.A.; Agurs-Collins, T.; Puckett, M.;
Richardson, L.C. Vital Signs: Trends in Incidence of Cancers Associated with Overweight and Obesity—United
States, 2005–2014. MMWR Morb. Mortal. Wkly. Rep. 2017, 66, 1052–1058. [CrossRef]
11. Santoni, M.; Cimadamore, A.; Massari, F.; Piva, F.; Aurilio, G.; Martignetti, A.; Scarpelli, M.; Di Nunno, V.;
Gatto, L.; Battelli, N.; et al. Key Role of Obesity in Genitourinary Tumors with Emphasis on Urothelial and
Prostate Cancers. Cancers 2019, 11, 1225. [CrossRef]
12. Massari, F.; Ciccarese, C.; Santoni, M.; Iacovelli, R.; Mazzucchelli, R.; Piva, F.; Scarpelli, M.; Berardi, R.;
Tortora, G.; Lopez-Beltran, A.; et al. Metabolic phenotype of bladder cancer. Cancer Treat. Rev. 2016, 45, 46–57.
[CrossRef]
13. Stone, T.W.; McPherson, M.; Gail Darlington, L. Obesity and Cancer: Existing and New Hypotheses for a
Causal Connection. EBioMedicine 2018, 30, 14–28. [CrossRef] [PubMed]
14. Ulrich, C.M.; Himbert, C.; Holowatyj, A.N.; Hursting, S.D. Energy balance and gastrointestinal cancer: Risk,
interventions, outcomes and mechanisms. Nat. Rev. Gastroenterol. Hepatol. 2018, 15, 683–698. [CrossRef]
15. Gao, Q.; Zheng, J.; Yao, X.; Peng, B. Adiponectin inhibits VEGF-A in prostate cancer cells. Tumour Biol. 2015,
36, 4287–4292. [CrossRef] [PubMed]
16. Lengyel, E.; Makowski, L.; DiGiovanni, J.; Kolonin, M.G. Cancer as a Matter of Fat: The Crosstalk between
Adipose Tissue and Tumors. Trends Cancer 2018, 4, 374–384. [CrossRef]
17. Romero, I.L.; Mukherjee, A.; Kenny, H.A.; Litchfield, L.M.; Lengyel, E. Molecular pathways: Trafficking of
metabolic resources in the tumor microenvironment. Clin. Cancer Res. 2015, 21, 680–686. [CrossRef]
18. Hotamisligil, G.S.; Bernlohr, D.A. Metabolic functions of FABPs–mechanisms and therapeutic implications.
Nat. Rev. Endocrinol. 2015, 11, 592–605. [CrossRef]
19. Hancke, K.; Grubeck, D.; Hauser, N.; Kreienberg, R.; Weiss, J.M. Adipocyte fatty acid-binding protein as a
novel prognostic factor in obese breast cancer patients. Breast Cancer Res. Treat. 2010, 119, 367–377. [CrossRef]
20. Hao, J.; Zhang, Y.; Yan, X.; Yan, F.; Sun, Y.; Zeng, J.; Waigel, S.; Yin, Y.; Fraig, M.M.; Egilmez, N.K.;
et al. Circulating Adipose Fatty Acid Binding Protein Is a New Link Underlying Obesity-Associated
Breast/Mammary Tumor Development. Cell Metab. 2018, 28, 689–705. [CrossRef]
21. Greenhill, C. A-FABP links obesity and breast cancer. Nat. Rev. Endocrinol. 2018, 14, 566. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2019, 20, 5683 11 of 13
22. Amin, M.B.; Greene, F.L.; Edge, S.B.; Compton, C.C.; Gershenwald, J.E.; Brookland, R.K.; Meyer, L.;
Gress, D.M.; Byrd, D.R.; Winchester, D.P. The Eighth Edition AJCC Cancer Staging Manual: Continuing to
build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer
J. Clin. 2017, 67, 93–99. [CrossRef] [PubMed]
23. Trpkov, K.; Grignon, D.J.; Bonsib, S.M.; Amin, M.B.; Billis, A.; Lopez-Beltran, A.; Samaratunga, H.; Tamboli, P.;
Delahunt, B.; Egevad, L.; et al. Handling and staging of renal cell carcinoma. The international society of
urological pathology consensus (ISUP) conference recommendations. Am. J. Surg. Pathol. 2013, 37, 1505–1517.
[CrossRef] [PubMed]
24. Moch, H.; Humphrey, P.A.; Ulbright, T.M.; Reuter, V.E. World Health Organization (WHO) Classification of
Tumours of the Urinary System and Male Genital Organs, 4th ed.; IARC: Lyon, France, 2016.
25. Samaratunga, H.; Gianduzzo, T.; Delahunt, B. The ISUP system of staging, grading and classification of renal
cell neoplasia. J. Kidney Cancer VHL 2014, 1, 26–39. [CrossRef]
26. Cimadamore, A.; Palagonia, E.; Piccinni, P.; Misericordia, M.; Galosi, A.B.; Montironi, R. Inguinal bladder
hernia with lipomatosis of the bladder wall: A potential clinical pitfall for cancer. Urologia 2019, 86, 35–38.
[CrossRef]
27. Wahal, S.P.; Mardi, K. Idiopathic renal replacement lipomatosis: A rare renal pseudo tumor. J. Cancer Res. Ther.
2014, 10, 428–430. [CrossRef]
28. Bonsib, S.M. The renal sinus is the principal invasive pathway: A prospective study of 100 renal cell
carcinomas. Am. J. Surg. Pathol. 2004, 28, 1594–1600. [CrossRef]
29. Thompson, R.H.; Leibovich, B.C.; Cheville, J.C.; Webster, W.S.; Lohse, C.M.; Kwon, E.D.; Frank, I.; Zincke, H.;
Blute, M.L. Is renal sinus fat invasion the same as perinephric fat invasion for pT3a renal cell carcinoma?
J. Urol. 2005, 174, 1218–1221. [CrossRef]
30. Grignon, D.; Paner, G.P. Renal cell carcinoma and the renal sinus. Adv. Anat. Pathol. 2007, 14, 63–68. [CrossRef]
31. Srigley, J.R.; Delahunt, B.; Eble, J.N.; Egevad, L.; Epstein, J.I.; Grignon, D.; Hes, O.; Moch, H.; Montironi, R.;
Tickoo, S.K.; et al. The International Society of Urological Pathology (ISUP) Vancouver Classification of
Renal Neoplasia. Am. J. Surg. Pathol. 2013, 37, 1469–1489. [CrossRef]
32. Bonsib, S.M.; Gibson, D.; Mhoon, M.; Greene, G.F. Renal sinus involvement in renal cell carcinomas. Am. J.
Surg. Pathol. 2000, 24, 451–458. [CrossRef] [PubMed]
33. Thompson, R.H.; Blute, M.L.; Krambeck, A.E.; Lohse, C.M.; Magera, J.S.; Leibovich, B.C.; Kwon, E.D.;
Frank, I.; Cheville, J.C. Patients with pT1 renal cell carcinoma who die from disease after nephrectomy may
have unrecognized renal sinus fat invasion. Am. J. Surg. Pathol. 2007, 31, 1089–1093. [CrossRef] [PubMed]
34. Bertini, R.; Roscigno, M.; Freschi, M.; Strada, E.; Petralia, G.; Pasta, A.; Matloob, R.; Sozzi, F.; Da Pozzo, L.;
Colombo, R.; et al. Renal sinus fat invasion in pT3a clear cell renal cell carcinoma affects outcomes of patients
without nodal involvement or distant metastases. J. Urol. 2009, 181, 2027–2032. [CrossRef] [PubMed]
35. Margulis, V.; Tamboli, P.; Martin, S.F.; Meisner, M.; Swanson, D.A.; Wood, C.G. Location of extrarenal tumor
expression does not impact survival of patients with pT3a renal cell carcinoma. J. Urol. 2007, 178, 1878–1882.
[CrossRef]
36. Delahunt, B. Advances and controversies in grading and staging of renal cell carcinoma. Mod. Pathol. 2009,
22, S24–S36. [CrossRef]
37. Chow, W.H.; McLaughlin, J.K.; Mandel, J.S.; Wacholder, S.; Niwa, S.; Fraumeni, J.F., Jr. Obesity and risk of
renal cell cancer. Cancer Epidemiol. Prev. Biomark. 1996, 5, 17–21.
38. Setiawan, V.W.; Stram, D.O.; Nomura, A.M.; Kolonel, L.N.; Henderson, B.E. Risk factors for renal cell cancer:
The multiethnic cohort. Am. J. Epidemiol. 2007, 166, 932–940. [CrossRef]
39. Adams, K.F.; Leitzmann, M.F.; Albanes, D.; Kipnis, V.; Moore, S.C.; Schatzkin, A.; Chow, W.H. Body size and
renal cell cancer incidence in a large US cohort study. Am. J. Epidemiol. 2008, 168, 268–277. [CrossRef]
40. Dobbins, M.; Decorby, K.; Choi, B.C. The Association between Obesity and Cancer Risk: A Meta-Analysis of
Observational Studies from 1985 to 2011. ISRN Prev. Med. 2013, 2013, 680536. [CrossRef]
41. Samanic, C.; Chow, W.H.; Gridley, G.; Jarvholm, B.; Fraumeni, J.F., Jr. Relation of body mass index to cancer
risk in 362,552 Swedish men. Cancer Causes Control 2006, 17, 901–909. [CrossRef]
42. Martini, D.J.; Liu, Y.; Shabto, J.M.; Carthon, B.C.; Russler, G.; Hitron, E.; Caulfield, S.; Kissick, H.; Harris, W.;
Kucuk, O.; et al. Novel risk stratification criteria of metastatic renal cell carcinoma (mRCC) patients (pts)
treated with immune checkpoint inhibitors (ICI). ASCO Genitourin. Cancer 2019, 37, e16068. [CrossRef]
Int. J. Mol. Sci. 2019, 20, 5683 12 of 13
43. Sidaway, P. Kidney cancer: Methylation of obesity-related genes is associated with prognosis. Nat. Rev. Urol.
2017, 14, 452. [CrossRef]
44. Wang, Q.; Tu, H.; Zhu, M.; Liang, D.; Ye, Y.; Chang, D.W.; Long, Y.; Wu, X. Circulating obesity-driven
biomarkers are associated with risk of clear cell renal cell carcinoma: A two-stage, case-control study.
Carcinogenesis 2019, 40, 1191–1197. [CrossRef]
45. Horiguchi, A.; Asano, T.; Asano, T.; Ito, K.; Sumitomo, M.; Hayakawa, M. Fatty acid synthase over expression is
an indicator of tumor aggressiveness and poor prognosis in renal cell carcinoma. J. Urol. 2008, 180, 1137–1140.
[CrossRef]
46. Menendez, J.A.; Lupu, R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat. Rev.
Cancer 2007, 7, 763–777. [CrossRef]
47. Albiges, L.; Hakimi, A.A.; Xie, W.; McKay, R.R.; Simantov, R.; Lin, X.; Lee, J.L.; Rini, B.I.; Srinivas, S.;
Bjarnason, G.A.; et al. Body mass index and metastatic renal cell carcinoma: Clinical and biological
correlations. J. Clin. Oncol. 2016, 34, 3655–3663. [CrossRef]
48. Häggström, C.; Rapp, K.; Stocks, T.; Manjer, J.; Bjørge, T.; Ulmer, H.; Engeland, A.; Almqvist, M.; Concin, H.;
Selmer, R. Metabolic factors associated with risk of renal cell carcinoma. PLoS ONE 2013, 8, e57475. [CrossRef]
49. Steffens, S.; Grünwald, V.; Ringe, K.I.; Seidel, C.; Eggers, H.; Schrader, M.; Wacker, F.; Kuczyk, M.A.;
Schrader, A.J. Does obesity influence the prognosis of metastatic renal cell carcinoma in patients treated with
vascular endothelial growth factor-targeted therapy? Oncologist 2011, 16, 1565–1571. [CrossRef]
50. Ladoire, S.; Bonnetain, F.; Gauthier, M.; Zanetta, S.; Petit, J.M.; Guiu, S.; Kermarrec, I.; Mourey, E.; Michel, F.;
Krause, D.; et al. Visceral fat area as a new independent predictive factor of survival in patients with
metastatic renal cell carcinoma treated with antiangiogenic agents. Oncologist 2011, 16, 71–81. [CrossRef]
51. Mizuno, R.; Miyajima, A.; Hibi, T.; Masuda, A.; Shinojima, T.; Kikuchi, E.; Jinzaki, M.; Oya, M. Impact of
baseline visceral fat accumulation on prognosis in patients with metastatic renal cell carcinoma treated with
systemic therapy. Med. Oncol. 2017, 34, 47. [CrossRef]
52. Choueiri, T.K.; Xie, W.; Kollmannsberger, C.K.; Rini, B.I.; McDermott, D.F.; Knox, J.J.; Heng, D.Y. The impact
of body mass index (BMI) and body surface area (BSA) on treatment outcome to vascular endothelial
growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma: Results from a large international
collaboration. J. Clin. Oncol. 2019, 28, 4524. [CrossRef]
53. Ishihara, H.; Kondo, T.; Omae, K.; Takagi, T.; Iizuka, J.; Kobayashi, H.; Tanabe, K. Sarcopenia and the Modified
Glasgow Prognostic Score are Significant Predictors of Survival Among Patients with Metastatic Renal Cell
Carcinoma Who are Receiving First-Line Sunitinib Treatment. Target. Oncol. 2016, 11, 605–617. [CrossRef]
54. Martini, D.J.; Shabto, J.M.; Liu, Y.; Carthon, B.C.; Speak, A.; Hitron, E.; Russler, G.; Caulfield, S.; Ogan, K.;
Harris, W.; et al. Body mass index (BMI) and toxicities and association with clinical outcomes (CO) in
metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (cabo). J. Clin. Oncol. 2019,
37, 613. [CrossRef]
55. Lalani, A.A.; Xie, W.; Flippot, R.; Steinharter, J.A.; Harshman, L.C.; McGregor, B.A.; Heng, D.Y.C.; Choueiri, T.K.
Impact of body mass index (BMI) on treatment outcomes to immune checkpoint blockade (ICB) in metastatic
renal cell carcinoma (mRCC). J. Clin. Oncol. 2019, 37, 566. [CrossRef]
56. De Giorgi, U.; Procopio, G.; Giannarelli, D.; Sabbatini, R.; Bearz, A.; Buti, S.; Basso, U.; Mitterer, M.; Ortega, C.;
Bidoli, P.; et al. Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients
with Renal Cell Cancer Treated with Nivolumab. Clin. Cancer Res. 2019, 25, 3839–3846. [CrossRef]
57. Motzer, R.J.; Penkov, K.; Haanen, J.; Rini, B.; Albiges, L.; Campbell, M.T.; Venugopal, B.; Kollmannsberger, C.;
Negrier, S.; Uemura, M.; et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
N. Engl. J. Med. 2019, 380, 1103–1115. [CrossRef]
58. Renfro, L.A.; Loupakis, F.; Adams, R.A.; Seymour, M.T.; Heinemann, V.; Schmoll, H.J.; Douillard, J.Y.;
Hurwitz, H.; Fuchs, C.S.; Diaz-Rubio, E.; et al. Body mass index is prognostic in metastatic colorectal
Cancer: pooled analysis of patients from first-line clinical trials in the ARCAD database. J. Clin. Oncol. 2016,
34, 144–150. [CrossRef]
59. Routy, B.; Le Chatelier, E.; Derosa, L.; Duong, C.P.M.; Alou, M.T.; Daillère, R.; Fluckiger, A.; Messaoudene, M.;
Rauber, C.; Roberti, M.P.; et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against
epithelial tumors. Science 2018, 359, 91–97. [CrossRef]
60. Dao, M.C.; Clément, K. Gut microbiota and obesity: Concepts relevant to clinical care. Eur. J. Int. Med. 2018,
48, 18–24. [CrossRef]
Int. J. Mol. Sci. 2019, 20, 5683 13 of 13
61. Daquinag, A.C.; Dadbin, A.; Snyder, B.; Wang, X.; Sahin, A.A.; Ueno, N.T.; Kolonin, M. Non-glycanated
Decorin Is a Drug Target on Human Adipose Stromal Cells. Mol. Ther. Oncolytics 2017, 6, 1–9. [CrossRef]
62. Daquinag, A.C.; Tseng, C.; Zhang, Y.; Amaya-Manzanares, F.; Florez, F.; Dadbin, A.; Zhang, T.; Kolonin, M.G.
Targeted Proapoptotic Peptides Depleting Adipose Stromal Cells Inhibit Tumor Growth. Mol. Ther. 2016,
24, 34–40. [CrossRef] [PubMed]
63. Cozzo, A.J.; Sundaram, S.; Zattra, O.; Qin, Y.; Freemerman, A.J.; Essaid, L.; Darr, D.B.; Montgomery, S.A.;
McNaughton, K.K.; Ezzell, J.A.; et al. cMET inhibitor crizotinib impairs angiogenesis and reduces tumor
burden in the C3(1)-Tag model of basal-like breast cancer. Springerplus 2016, 5, 348. [CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
